<DOC>
	<DOCNO>NCT01957007</DOCNO>
	<brief_summary>This open-label Phase 1b dose-escalation study ass safety , tolerability , PK vantictumab combine docetaxel .</brief_summary>
	<brief_title>A Study Vantictumab ( OMP-18R5 ) Combination With Docetaxel Patients With Previously Treated NSCLC</brief_title>
	<detailed_description>Once maximum tolerate dose ( MTD ) maximum administer dose ( MAD ) determine , 10 patient may enrol cohort-expansion phase well characterize safety , tolerability PK vantictumab combine docetaxel . Up approximately 34 patient may enrol study .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Signed Informed Consent Form Age ≥18 year Histologically document recurrent advance ( Stage IV ) NSCLC Eastern CooperativeOncology Group ( ECOG ) performance status 0 1 All acute treatmentrelated toxicity prior therapy must resolve Grade ≤ 1 prior study entry Adequate hematologic endorgan function Evaluable measurable disease per RECIST v1.1 For woman childbearing potential men partner childbearing potential , agreement use two effective form contraception Prior treatment docetaxel recurrent advance NSCLC More two regimen systemic cytotoxic chemotherapy recurrent advance NSCLC Treatment anticancer therapy within 3 week prior initiation study treatment Known hypersensitivity component study treatment Grade ≥ 2 sensory neuropathy Uncontrolled seizure disorder active neurologic disease Untreated brain metastasis Leptomeningeal disease manifestation cancer Active infection require antibiotic Bisphosphonate therapy symptomatic hypercalcemia Known history clinically significant liver disease , include active viral hepatitis cirrhosis Significant intercurrent illness include , limited , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnancy , lactation , breastfeed Known HIV infection Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Concurrent use therapeutic warfarin New York Heart Association Classification III IV ( see Appendix E ) Known clinically significant gastrointestinal disease include , limited , inflammatory bowel disease Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior first dose study treatment anticipation need major surgical procedure course study Osteoporosis base Tscore &lt; 2.5 leave right total hip , leave right femoral neck lumbar spine ( L1L4 ) determine DEXA scan Bone metastases one following : Prior history pathologic fracture Lytic lesion require impend orthopedic intervention Lack treatment bisphosphonate denosumab Treatment thiazolidinedione PPAR gamma inhibitor ; e.g . Actos® ( pioglitazone ) , Avandia® ( rosiglitzone ) Active treatment oral IV glucocortocoid ≥4 week daily dose equivalent great 7.5 mg oral prednisone Fasting βCTX &gt; 1000 pg/mL Metabolic bone disease , hyperparathyroidism , Paget 's disease osteomalacia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>dose escalation</keyword>
	<keyword>histologically confirm</keyword>
	<keyword>malignancy metastatic</keyword>
</DOC>